Q: If you were to invest in the gene editing space, how would you rank these two?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Peter; Could you updates your thoughts on BLUE ? Thanks
Rod
Rod
Q: Hi team,
Grateful for your views on Oncorus (oncr-a). Apparently, the CEO was previously head of oncology at Moderna. Any other favorites for growth in the field of immunotherapy ?
With great appreciation for your work,
Jacques IDS
Grateful for your views on Oncorus (oncr-a). Apparently, the CEO was previously head of oncology at Moderna. Any other favorites for growth in the field of immunotherapy ?
With great appreciation for your work,
Jacques IDS
Q: Do you have any information or an opinion on this US company?
Phil
Phil
Q: Hi guys,
I already own PLI (3%) and I purchased BLUE. US last year around $70.00. I sold BLUE in September around $ 105 (happy but now NOT). Your thoughts about getting back in (1%).
Thanks,
Jim
I already own PLI (3%) and I purchased BLUE. US last year around $70.00. I sold BLUE in September around $ 105 (happy but now NOT). Your thoughts about getting back in (1%).
Thanks,
Jim
-
Biogen Inc. (BIIB $134.46)
-
Celgene Corporation (CELG $108.24)
-
Gilead Sciences Inc. (GILD $111.06)
-
iShares Biotechnology ETF (IBB $129.33)
-
bluebird bio Inc. (BLUE)
Q: Would you put money into biotech seasonally ? In the past I have done well on Celgene ... However , I have taken quite a hit on Gillead, so I am cautious.
Or should I look at the ETFs for a broader/safer play ?
Or should I look at the ETFs for a broader/safer play ?
Q: Hi guys,
Just wondering if you could do a little research on this U.S. company (Bluebird Bio - blue) and let me know how their books look and how close are they to bringing something to market.
Thanks,
Jim
Just wondering if you could do a little research on this U.S. company (Bluebird Bio - blue) and let me know how their books look and how close are they to bringing something to market.
Thanks,
Jim